View ValuationCKD Bio 향후 성장Future 기준 점검 0/6현재 CKD Bio 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보n/a이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장22.3%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지None마지막 업데이트n/a최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Feb 27CKD Bio Corp., Annual General Meeting, Mar 26, 2026CKD Bio Corp., Annual General Meeting, Mar 26, 2026, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, osong-eup, heungdeok-gu, chungcheongbuk-do, cheongju South Korea공고 • Feb 26CKD Bio Corp., Annual General Meeting, Mar 26, 2025CKD Bio Corp., Annual General Meeting, Mar 26, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, heungdeok-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Minor Risk Market cap is less than US$100m (₩119.6b market cap, or US$85.0m).New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.8b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩132.8b market cap, or US$96.4m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 76% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩122.3b market cap, or US$88.6m).New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.1b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 81% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩131.1b market cap, or US$99.2m).Reported Earnings • May 19First quarter 2023 earnings released: ₩530 loss per share (vs ₩220 loss in 1Q 2022)First quarter 2023 results: ₩530 loss per share (further deteriorated from ₩220 loss in 1Q 2022). Revenue: ₩43.7b (down 6.8% from 1Q 2022). Net loss: ₩2.91b (loss widened 141% from 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 17Full year 2022 earnings released: ₩3,045 loss per share (vs ₩1,199 loss in FY 2021)Full year 2022 results: ₩3,045 loss per share (further deteriorated from ₩1,199 loss in FY 2021). Revenue: ₩156.0b (up 9.7% from FY 2021). Net loss: ₩16.7b (loss widened 154% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).Upcoming Dividend • Dec 22Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).Reported Earnings • May 23First quarter 2021 earnings released: ₩357 loss per share (vs ₩460 profit in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: ₩33.5b (up 10% from 1Q 2020). Net loss: ₩1.96b (down 179% from profit in 1Q 2020).Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 34% share price gain to ₩77,400, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 263% over the past three years.Reported Earnings • Mar 21Full year 2020 earnings released: EPS ₩1,147 (vs ₩2,391 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩124.6b (down 9.2% from FY 2019). Net income: ₩6.21b (down 49% from FY 2019). Profit margin: 5.0% (down from 8.9% in FY 2019). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩61,700, the stock is trading at a trailing P/E ratio of 32.3x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 175%.공고 • Mar 06CKD Bio Corp., Annual General Meeting, Mar 26, 2021CKD Bio Corp., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Mar 01New 90-day low: ₩65,900The company is down 2.0% from its price of ₩67,400 on 01 December 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period.분석 기사 • Feb 28What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor CompositionThe big shareholder groups in CKD Bio Corp. ( KRX:063160 ) have power over the company. Large companies usually have...분석 기사 • Feb 01Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?It might be of some concern to shareholders to see the CKD Bio Corp. ( KRX:063160 ) share price down 12% in the last...분석 기사 • Jan 11CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩77,500, the stock is trading at a trailing P/E ratio of 40.5x, down from the previous P/E ratio of 49x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 288%.Upcoming Dividend • Dec 22Upcoming Dividend of ₩190 Per ShareWill be paid on the 6th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.2% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.6%).분석 기사 • Dec 21What CKD Bio Corp.'s (KRX:063160) ROE Can Tell UsWhile some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Is New 90 Day High Low • Dec 18New 90-day high: ₩102,000The company is up 101% from its price of ₩50,700 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩101,000, the stock is trading at a trailing P/E ratio of 52.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 413%.분석 기사 • Nov 30Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...Is New 90 Day High Low • Nov 30New 90-day high: ₩64,200The company is up 15% from its price of ₩55,800 on 01 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 19% share price gain to ₩64,200, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 201%.Reported Earnings • Nov 22Third quarter 2020 earnings released: EPS ₩252The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩32.7b (down 6.5% from 3Q 2019). Net income: ₩1.36b (down 59% from 3Q 2019). Profit margin: 4.2% (down from 9.5% in 3Q 2019). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 30% share price gain to ₩53,500, the stock is trading at a trailing P/E ratio of 23.3x, up from the previous P/E ratio of 17.9x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 157%.Is New 90 Day High Low • Oct 30New 90-day low: ₩39,250The company is down 1.0% from its price of ₩39,450 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.이익 및 매출 성장 예측KOSE:A063160 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2024194,500N/AN/AN/A19/30/2023159,935-23,130-25,355-16,588N/A6/30/2023155,183-20,233-20,483-11,038N/A3/31/2023152,876-18,403-15,290-8,075N/A12/31/2022156,042-16,703-10,435-3,205N/A9/30/2022154,395-10,462-6,8371,239N/A6/30/2022154,759-11,222-10,230721N/A3/31/2022155,569-5,821-15,703-436N/A12/31/2021142,238-6,577-26,588-5,882N/A9/30/2021135,760-6,730-30,532-7,506N/A6/30/2021130,483-1,111-40,416-6,503N/A3/31/2021127,7411,771-52,783-3,114N/A12/31/2020124,6006,207-57,7854,824N/A9/30/2020135,77310,664-61,9036,278N/A6/30/2020138,04212,633-56,65110,401N/A3/31/2020136,26512,446-36,09419,449N/A12/31/2019137,18412,265-30,81716,990N/A9/30/2019129,52910,563-27,62719,152N/A6/30/2019127,1349,605-13,99019,668N/A12/31/2018124,5107,956-1,47715,536N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A063160 의 예상 수익 증가율이 절약률(3.1%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: A063160 의 수익이 KR 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: A063160 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: A063160 의 수익이 KR 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: A063160 의 수익이 연간 20%보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A063160의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/14 08:32종가2026/07/14 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CKD Bio Corp.는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kyung-rae HanDaishin Securities Co. Ltd.Han Kyung KimLS Securities Co., Ltd.NaYeon KimNH Investment & Securities Co., Ltd.2명의 분석가 더 보기
공고 • Feb 27CKD Bio Corp., Annual General Meeting, Mar 26, 2026CKD Bio Corp., Annual General Meeting, Mar 26, 2026, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, osong-eup, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
공고 • Feb 26CKD Bio Corp., Annual General Meeting, Mar 26, 2025CKD Bio Corp., Annual General Meeting, Mar 26, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Minor Risk Market cap is less than US$100m (₩119.6b market cap, or US$85.0m).
New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.8b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩132.8b market cap, or US$96.4m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 76% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩122.3b market cap, or US$88.6m).
New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.1b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 81% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩131.1b market cap, or US$99.2m).
Reported Earnings • May 19First quarter 2023 earnings released: ₩530 loss per share (vs ₩220 loss in 1Q 2022)First quarter 2023 results: ₩530 loss per share (further deteriorated from ₩220 loss in 1Q 2022). Revenue: ₩43.7b (down 6.8% from 1Q 2022). Net loss: ₩2.91b (loss widened 141% from 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 17Full year 2022 earnings released: ₩3,045 loss per share (vs ₩1,199 loss in FY 2021)Full year 2022 results: ₩3,045 loss per share (further deteriorated from ₩1,199 loss in FY 2021). Revenue: ₩156.0b (up 9.7% from FY 2021). Net loss: ₩16.7b (loss widened 154% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).
Upcoming Dividend • Dec 22Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).
Reported Earnings • May 23First quarter 2021 earnings released: ₩357 loss per share (vs ₩460 profit in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: ₩33.5b (up 10% from 1Q 2020). Net loss: ₩1.96b (down 179% from profit in 1Q 2020).
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 34% share price gain to ₩77,400, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 263% over the past three years.
Reported Earnings • Mar 21Full year 2020 earnings released: EPS ₩1,147 (vs ₩2,391 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩124.6b (down 9.2% from FY 2019). Net income: ₩6.21b (down 49% from FY 2019). Profit margin: 5.0% (down from 8.9% in FY 2019). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩61,700, the stock is trading at a trailing P/E ratio of 32.3x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 175%.
공고 • Mar 06CKD Bio Corp., Annual General Meeting, Mar 26, 2021CKD Bio Corp., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Mar 01New 90-day low: ₩65,900The company is down 2.0% from its price of ₩67,400 on 01 December 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period.
분석 기사 • Feb 28What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor CompositionThe big shareholder groups in CKD Bio Corp. ( KRX:063160 ) have power over the company. Large companies usually have...
분석 기사 • Feb 01Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?It might be of some concern to shareholders to see the CKD Bio Corp. ( KRX:063160 ) share price down 12% in the last...
분석 기사 • Jan 11CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩77,500, the stock is trading at a trailing P/E ratio of 40.5x, down from the previous P/E ratio of 49x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 288%.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩190 Per ShareWill be paid on the 6th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.2% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.6%).
분석 기사 • Dec 21What CKD Bio Corp.'s (KRX:063160) ROE Can Tell UsWhile some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Is New 90 Day High Low • Dec 18New 90-day high: ₩102,000The company is up 101% from its price of ₩50,700 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩101,000, the stock is trading at a trailing P/E ratio of 52.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 413%.
분석 기사 • Nov 30Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Is New 90 Day High Low • Nov 30New 90-day high: ₩64,200The company is up 15% from its price of ₩55,800 on 01 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 19% share price gain to ₩64,200, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 201%.
Reported Earnings • Nov 22Third quarter 2020 earnings released: EPS ₩252The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩32.7b (down 6.5% from 3Q 2019). Net income: ₩1.36b (down 59% from 3Q 2019). Profit margin: 4.2% (down from 9.5% in 3Q 2019). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 30% share price gain to ₩53,500, the stock is trading at a trailing P/E ratio of 23.3x, up from the previous P/E ratio of 17.9x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 157%.
Is New 90 Day High Low • Oct 30New 90-day low: ₩39,250The company is down 1.0% from its price of ₩39,450 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.